Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 in unresectable stage III or IV malignant melanoma
ACTRN12606000010594Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Planned start Mar 2006; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12606000010594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000010594.